New Funding for Kineta Inc.'s Novel Antiviral Program Targeting the Spectrum of Global Diseases

Published: Aug 12, 2011

SEATTLE--(BUSINESS WIRE)--Kineta, Inc. announced today its next generation antiviral program has received a 2.8 million dollar grant from the National Institute of Allergy and Infectious Disease, a part of the National Institutes of Health (NIH). Awarded under the Small Business Innovation Research (SBIR) program, the prestigious phase two grant will provide on-going support for Kineta’s work on a new class of antiviral drugs targeting an array of global, deadly viruses.

Back to news